Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
April 11, 2017 09:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today preliminary results from the expanded stage of its phase I study, EBOV-001. The...
Inovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability to Induce Remission of HIV Infection and End Lifetime of Drug Therapy
March 30, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., March 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its academic and industry collaborators received a multi-year $6.95 million...
George Bickerstaff Elected to Inovio’s Board of Directors
March 21, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the election of George Bickerstaff to its Board of Directors. Mr....
Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results
March 15, 2017 16:05 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2016. Total...
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017
March 09, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 fourth...
Inovio’s SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy
February 27, 2017 07:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance...
Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases
February 23, 2017 07:00 ET
|
Inovio Pharmaceuticals
Significant immune responses observed in 100% of Zika-vaccinated subjects and 98% of MERS-vaccinated human subjects in separate phase I studies Data reported at Coalition for Epidemic...
Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China
February 13, 2017 06:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio...
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
January 30, 2017 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:...
Inovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study
December 21, 2016 08:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody...